Developing endpoints for the cognitive burden in myotonic dystrophy type 1: A workshop report

Myotonic Dystrophy Type 1 (DM1) is an autosomal dominant, repeat expansion, progressive multisystem disorder. While central nervous system (CNS) involvement has been well established, a consensus on a dedicated protocol to assess cognitive function and collect CNS biomarkers is still lacking in this disease. In the era of disease-modifying therapies that cross the blood-brain barrier (BBB), availability of mechanistically relevant neuropsychological probes and reliable biomarkers of DM1 pathology is no longer deferrable. Consequently, to better define and harmonize a CNS assessment pathway, the Myotonic Dystrophy Clinical Research Network (DMCRN) convened a workshop entitled ‘‘Myotonic Dystrophy CNS Workshop’’ in September 2024. Presenters described the protean manifestations of CNS involvement in DM1, shared data about neuropsychological assessments available with cross-fertilization from other neurological and neurodegenerative diseases and discussed existing data and future perspectives on CNS radiological biomarkers.

Authors

Institutions

Publication Details

Journal
Journal of Neuromuscular Diseases
Published
2026-11-19
DOI
https://doi.org/10.1177/22143602261503402
Primary Topic
Genetic Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Developing endpoints for the cognitive burden in myotonic dystrophy type 1: A workshop report

Eric T. Wang, Nicholas Elwood Johnson, Julie B. Eisengart, Valeria Sansone et al.
Journal of Neuromuscular Diseases
Genetic Neurodegenerative Diseases
article

Developing endpoints for the cognitive burden in myotonic dystrophy type 1: A workshop report

Eric T. Wang, Nicholas Elwood Johnson, Julie B. Eisengart, Valeria Sansone, Carola Rita Ferrari Aggradi, Belinda S. Pinto, Belen Esparis, Eric C. Porges, James Matthew Bjork, Dorene M. Rentz, Sub H. Subramony
article en

Abstract

Myotonic Dystrophy Type 1 (DM1) is an autosomal dominant, repeat expansion, progressive multisystem disorder. While central nervous system (CNS) involvement has been well established, a consensus on a dedicated protocol to assess cognitive function and collect CNS biomarkers is still lacking in this disease. In the era of disease-modifying therapies that cross the blood-brain barrier (BBB), availability of mechanistically relevant neuropsychological probes and reliable biomarkers of DM1 pathology is no longer deferrable. Consequently, to better define and harmonize a CNS assessment pathway, the Myotonic Dystrophy Clinical Research Network (DMCRN) convened a workshop entitled ‘‘Myotonic Dystrophy CNS Workshop’’ in September 2024. Presenters described the protean manifestations of CNS involvement in DM1, shared data about neuropsychological assessments available with cross-fertilization from other neurological and neurodegenerative diseases and discussed existing data and future perspectives on CNS radiological biomarkers.

Journal of Neuromuscular Diseases
University of Minnesota (US), Harvard University (US), Virginia Commonwealth University (US), University of Milan (IT), University of California, Irvine (US), University of Florida (US), University of Pennsylvania (US)
Genetic Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon